A 50 year old male Patient is with difficulty of urinating know hypertensive stage 1 and T2DM on maintance Telmisartan 40mg and metformin 500mg tab t2dm is not in control. The main concern of the patient difficulty of peeing (urination) from last 6 months no pain while urinating but feeling of not fully emptying bladder, partially urinating no meds taken no consultation. PMH: Hypertensive stage 2 diagnosed 2019 T2DM diagnosed 2019 Left ventricular hypertrophy dur uncontrolled HTN diagnosed 2020 What would be the diagnosis treatment and management

Reading File
Reading File
Reading File
Searching the Web

2024 AUA guideline BPH lower urinary tract symptoms evaluation post void residual urinalysis PSA alpha blocker

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"prostatic hyperplasia"[MeSH Terms] AND "lower urinary tract symptoms"

Searching PubMed

"urinary retention"[MeSH Terms] AND diabetes

Reading File
Reading File
Reading File
Finding Sources
Reading Web Page

https://www.auanet.org/documents/guidelines/pdf/bph%20surgic…

Reading File
Reading File
Finding Sources
Reading Article

PMID: 42095481

Reading Article

PMID: 42095477

This is chronic lower urinary tract symptoms (LUTS) with incomplete bladder emptying. In a 50-year-old man, the leading possibilities are:
  1. Benign prostatic hyperplasia (BPH) causing bladder outlet obstruction
    Most likely if there is weak stream, hesitancy, straining, intermittency, nocturia, or dribbling.
  2. Diabetic bladder dysfunction (diabetic cystopathy)
    Poorly controlled diabetes can damage bladder nerves and muscle, causing reduced bladder sensation, weak contraction, increased post-void residual urine, hesitancy, and incomplete emptying. This can coexist with BPH. Campbell-Walsh-Wein Urology, p. 3491. Harrison also describes diabetic cystopathy as impaired sensation and failure to empty, followed by increased residual urine and recurrent UTI risk.
  3. Conditions that must be excluded before labeling this as BPH alone:
    • Urinary tract infection, even if painless
    • Urethral stricture
    • Prostatitis
    • Bladder stone
    • Chronic urinary retention with hydronephrosis or kidney impairment
    • Prostate cancer, especially if abnormal digital rectal examination or PSA, though cancer is not the usual cause of these symptoms
    • Medication-related retention, constipation, neurologic disease

Urgency

He should have an in-person clinical assessment within days, preferably by a urologist, because the symptoms have persisted for 6 months and diabetes is uncontrolled.
Go to emergency care today if he develops:
  • Complete inability to pass urine
  • Painful/distended lower abdomen
  • Fever, chills, vomiting, or flank pain
  • Visible blood in urine
  • New leg weakness, saddle numbness, or loss of bowel control
  • Marked drowsiness, dehydration, or very high blood glucose symptoms

Recommended evaluation

The diagnosis cannot be made safely from symptoms alone. A focused work-up should include:
AssessmentPurpose
History and IPSS/AUA symptom scoreGrade severity and effect on daily life
Physical examinationAbdomen for distended bladder, neurologic exam, blood pressure, genital exam
Digital rectal examinationAssess prostate size, texture, nodules, tenderness
Urinalysis with urine culture if indicatedLook for UTI, blood, glucose, protein
Post-void residual (PVR) by bladder scanEssential to determine retained urine
UroflowmetryMeasures urinary flow rate and helps identify obstruction or weak bladder contraction
Serum creatinine/eGFR and electrolytesCheck for kidney injury from retention and diabetic kidney disease
HbA1c, fasting/random glucoseAssess degree of uncontrolled diabetes
Urine albumin-creatinine ratioScreen for diabetic kidney disease
PSA after counseling and before starting finasteride/dutasterideSupports prostate assessment, but PSA alone does not diagnose cancer
Renal and bladder ultrasoundParticularly important if PVR is high, renal function is abnormal, or there is recurrent UTI/hematuria
Cystoscopy or urodynamicsUrology-directed if stricture, obstruction, high residual urine, or diabetic bladder dysfunction is suspected
The AUA evaluation framework supports history, examination, symptom scoring, and urinalysis initially, with PVR and uroflowmetry when needed. The newer AUA guideline also emphasizes that LUTS may arise from bladder, prostate, urethral, or other causes, so treatment should follow the evaluation rather than assuming BPH. See the AUA BPH evaluation guidance. Recent updated AUA guideline summaries are indexed as PMID 42095481 and PMID 42095477.

Likely initial treatment, after assessment

1. If BPH-related obstruction is likely and PVR is not dangerously high

A clinician may prescribe an alpha-1 blocker, commonly:
  • Tamsulosin 0.4 mg once daily, usually after the same meal each day, or
  • Alfuzosin, depending on availability and clinician judgment.
This typically improves flow and urinary symptoms within days to weeks.
Important in this patient: tamsulosin can cause dizziness, postural hypotension, and fainting. Because he already takes telmisartan, blood pressure should be reviewed and he should be advised to stand up slowly. A non-uroselective alpha-blocker such as doxazosin may reduce BP more substantially and is generally less attractive in someone already on antihypertensive treatment unless specifically selected and monitored.

2. If prostate enlargement is confirmed

If prostate size is enlarged or PSA supports increased prostate volume, a 5-alpha-reductase inhibitor may be added:
  • Finasteride 5 mg once daily, or
  • Dutasteride 0.5 mg once daily.
These shrink the prostate and reduce future acute urinary retention and surgery risk, but symptom improvement takes 6 to 12 months. They can cause reduced libido, erectile/ejaculatory dysfunction, and lower PSA values by about half, which must be accounted for during prostate-cancer assessment.
For clearly enlarged prostates and moderate-to-severe symptoms, combination treatment with an alpha-blocker plus finasteride/dutasteride may be appropriate.

3. If diabetic cystopathy or weak bladder contraction is significant

Do not simply add bladder-relaxing drugs before measuring PVR, because antimuscarinics can worsen retention.
Management may include:
  • Strict improvement of glycemic control
  • Timed voiding, for example every 3 to 4 hours while awake
  • Double voiding: urinate, wait briefly, then try again
  • Treat constipation
  • Intermittent self-catheterization if residual urine is persistently high or renal/UTI complications develop
  • Urodynamic testing to distinguish obstruction from poor detrusor contractility
Harrison states that diabetic cystopathy is managed with scheduled voiding or self-catheterization when appropriate.

4. If urinary retention is substantial

If he has a markedly raised PVR, palpable/distended bladder, renal impairment, hydronephrosis, or infection, he may require:
  • Prompt bladder drainage with a urethral catheter or suprapubic catheter
  • Urgent urology review
  • Assessment for obstruction and renal complications
  • Later definitive BPH treatment or catheterization plan, depending on the cause

Diabetes, blood pressure, and cardiac-risk management

This presentation should trigger a full review of his diabetes and cardiovascular treatment, not just urinary treatment.
  • Check HbA1c now and review home glucose values, diet, adherence, renal function, weight, and complications.
  • Metformin 500 mg alone may be inadequate, but it should not be increased or combined with other drugs without checking eGFR, HbA1c, and contraindications.
  • Because he has hypertension and prior LVH, his clinician should consider diabetes agents with cardiovascular and kidney benefit when indicated, such as an SGLT2 inhibitor or a GLP-1 receptor agonist. Selection depends on HbA1c, kidney function, weight, heart-failure status, affordability, and adverse-effect risks.
  • Continue telmisartan only as prescribed, but reassess BP, potassium, and creatinine. The history calls it both stage 1 and stage 2 hypertension, so current average BP readings are needed.
  • Check lipid profile and assess whether he needs statin therapy, which is commonly indicated in diabetes at age 50 depending on overall cardiovascular risk.

Practical plan for this patient

  1. Book a urology or primary-care appointment urgently, within 1 week.
  2. Obtain urinalysis, PVR bladder scan, creatinine/eGFR, HbA1c, urine albumin-creatinine ratio, and prostate assessment.
  3. Do not self-start tamsulosin, finasteride, antibiotics, or herbal “prostate” medicines.
  4. Avoid excess evening fluids, alcohol, and caffeine. Do not restrict fluids excessively if glucose is high or dehydrated.
  5. Treat constipation and avoid over-the-counter cold/allergy products containing decongestants or sedating antihistamines, which can precipitate urinary retention.
  6. Review response 4 to 12 weeks after treatment is started, sooner if symptoms worsen.
  7. Escalate to procedural BPH treatment if medication fails or if there are recurrent retention, recurrent UTI, bladder stones, gross hematuria due to BPH, kidney impairment/hydronephrosis, or patient preference.
Working diagnosis: LUTS with chronic incomplete bladder emptying, probably BPH with possible contribution from diabetic autonomic neuropathy/diabetic cystopathy. The PVR measurement, urinalysis, prostate examination, renal assessment, and glucose assessment are the key next steps.

What is AUA and pvr

Reading File
Finding Sources
Searching the Web

AUA American Urological Association post void residual PVR definition

Searching PubMed

"urinary retention"[MeSH Terms] AND "postvoid residual"

  • AUA = American Urological Association. It is a professional body for urology specialists that publishes clinical guidelines.
    • In some forms, AUA Symptom Score refers to a questionnaire, also called the IPSS (International Prostate Symptom Score), used to measure urinary symptoms such as weak stream, hesitancy, frequency, nocturia, and incomplete emptying.
  • PVR = post-void residual urine. It means the amount of urine left in the bladder immediately after the patient urinates.
PVR is measured using a quick bladder ultrasound scan, usually painless, or less commonly by inserting a catheter after urination.
For this patient, PVR is important because it shows whether the bladder is actually retaining urine:
  • Below 50 mL is often considered normal.
  • More than 200 mL, especially with symptoms, is concerning.
  • A high PVR can result from prostate obstruction (BPH) or from a weak bladder due to diabetic autonomic neuropathy. It needs clinical assessment because persistent retention can lead to UTIs and kidney problems.
The AUA explanation of PVR notes that it helps assess bladder emptying and can be measured by ultrasound or catheterization.
This is a shared conversation. Sign in to Orris to start your own chat.